M
any cell-and antibody (Ab)-mediated immunotherapies for viral infections or cancer recognize unique viral or tumor-associated antigens (Ags). The target epitopes typically comprise short polypeptide sequences, and these therapies are therefore susceptible to single nucleotide mutations that occur at an elevated frequency in the genomes of both neoplastic cells and viruses. [1] [2] [3] [4] Retroviruses, for instance, have a mutation rate as high as 3 ϫ 10 Ϫ5 mutations/bp/cycle of replication, 5 and although most of these mutations are biologically neutral and not adaptive, 6 specific Ag loss variants can develop in response to selective pressure arising from antiviral drugs or immune surveillance. [7] [8] [9] The genetic diversity of malignant cells can produce subpopulations of tumor cells with altered expression of tumor Ags, increased chemoresistance, and increased metastatic potential. This plasticity in the genomes of viruses and malignant cells presents a significant obstacle for chemotherapy, vaccines, and other immunotherapies. 8, 10 We have created chimeric immune receptors (CIRs) that redirect T cells to mediate the major histocompatibility complex class I-unrestricted lysis of cells expressing HIV envelope (HIV env ) or the pan-adenocarcinoma Ag TAG-72. The Ag specificity of these CIRs is derived from the extracellular domain of CD4, the ligand for the HIV env gp120, the single-chain Fv (scFv) region of the anti-HIV env gp41 Ab, 11, 12 or the anti-TAG-72 humanized Ab CC49. 13 TAG-72, like the carcinoembryonic Ag (CEA), 14 is a pan-adenocarcinoma oncofetal Ag. 15 The Ag recognition domain of all of these CIRs is linked to the intracellular-signaling domain of the CD3-subunit of the T-cell receptor (TCR), which, upon engagement of the receptor, induces T-cell activation, cytolytic function, and cytokine release. T cells expressing the CD4-and CC49-CIRs have been shown to kill HIV-infected cells 16, 17 and TAG-72-expressing tumor cells, 18 respectively. A second anticancer CIR comprising the humanized scFv of the Col-1 Ab, 19 which binds CEA and mediates the lysis of CEA-expressing human adenocarcinoma cells, was also generated.
To address the challenge of Ag loss variants escaping detection by CD4--, CC49--, and COL-1--expressing T cells, we have generated bispecific CIRs (BCIRs) that recognize multiple epitopes of the HIV env or multiple tumor Ags. BCIR-1 recognizes both TAG-72 and CEAs through the humanized scFv of the CC49 Ab and the C-terminal a 3 b 3 domain of CEA, which binds in an antiparallel fashion to the N-terminal domain of another CEA molecule. 20, 21 BCIR-2 recognizes two distinct epitopes in HIV env gp120 by combining the extracellular domains of CD4 and the scFv of the gp120-specific Ab 447D. BCIR-3 recognizes epitopes in HIV env gp120 and gp41 by combining the scFv of 447D and 98.6, an anti-gp41 Ab. 11, 12 Like the CIRs, all of the BCIRs include the signaling domains of the CD3-subunit of the TCR. We describe herein the construction of these anticancer and antiviral BCIRs and describe the activity of human primary T cells genetically modified to express them.
MATERIALS AND METHODS

CIR and BCIR constructs
The 447D anti-HIV env gp120 and 98.6 anti-HIV env gp41 Abs were provided by Dr. Zolla-Pazner (New York University Medical Center, New York, NY) and are described elsewhere. 11, 12 The construction of the anti-gp120 ligand CD4-and anti-gp41 single-chain Ab 98.6-monospecific CIRs are described by Roberts et al, 17 the anti-HIV env gp120 447D-scFv CIR is described by Patel et al, 22 and the anti-TAG-72 scFv CIR is described by McGuinness et al. 18 The BCIR-1 receptor (CC49-L205c-CEA(a 3 b 3 )-) directs the expression of a hybrid protein that consists of the V L secretion leader and scFv domain of CC49 joined at its C terminus (residue 245 of the mature scFv) through a 25-aa linker (SSADDAKKDAAKKDDAKKDDAKKDG (L205c)) to the a 3 b 3 region of CEA (residues 498 -675 of the mature polypeptide). The extracellular domains are joined through the C terminus of the CEA(a 3 b 3 ) domain to the CD4 transmembrane region (residues 372-395 of the mature polypeptide) and the CD3-cytoplasmic domains (residues 31-142 of the mature polypeptide).
Two types of anti-HIV env BCIR constructs were generated: scFv ligand chimeras and scFv-scFv chimeras, both of which included the TCR CD3--signaling domains. The Ag recognition units of the scFv ligand chimera 447D-CD4-(BCIR-2) comprised the scFv domains of the anti-gp120 Ab 447D fused to the V1 and V2 domains of CD4 (residues 1-180) through a linker. The Ag recognition units of the scFv-scFv chimera (BCIR-3) comprised the scFv of the anti-gp41 Ab 98.6 fused to the scFv domains of the anti-gp120 Ab 447D (described above) through a linker. Several linkers were tested in the BCIR constructs. The optimal linker for expression of both types of BCIR was the L205c linker (described above). Alternative linkers tested included DKTHTSPPSP, GSTSGSGKS-SEGKG, and GLQLEESSAEAQDGELD. The C-terminal amino acid of the CD4 V2 domain (residue 180) in BCIR-2 was fused to CD3-intracellular signaling domains (residues 31-142) through the V3, V4, and transmembrane domains of CD4 (residues 131-395). The C terminus of the 447D V72 variable domain (residue 113) in BCIR-3 was in turn linked to the hinge and Fc region of the human immunoglobulin G2 (IgG2) heavy chain (residues 226 -447), the 18-residue IgG3 M1 membrane hinge, the CD4 transmembrane domain (residues 372-395), and finally the CD3-intracellular signaling domain.
HIV target constructs
pIKenv is a vector designed to allow the efficient expression of HIV env in mammalian cells. 23 A pair of HIV env mutants that lacked either the CD4-or 447D-binding sites was created to test the specificity of the BCIR-2-and BCIR-3-expressing T cells. These HIV env mutants were created by oligonucleotidedirected mutagenesis with single-stranded pIKenv DNA. The 447D Ϫ env plasmid pIKenvR315Q/revϩ/tatϪ expresses a mutant HIV env polypeptide in which Arg-315 is replaced with Gln, and the CD4 Ϫ env plasmid pIKenvE370R/revϩ/tatϪ expresses a mutant HIV env polypeptide in which Glu-370 is replaced with Arg.
Generation of viral stock supernatants
At 2 days before transfection, TSA (a 293 cell subline) 24 cells were seeded at 5 ϫ 10 5 cells/10-cm culture dish. The TSA cells were transfected by the calcium phosphate coprecipitation method with 10 g of retroviral vector pRT43.2 encoding the CIR of interest and 5 g of packaging plasmid. The medium was changed at 24 hours posttransfection, and culture supernatants were harvested and filtered 24 hours later.
Culture and transduction of human T cells
Peripheral blood mononuclear cells (PBMCs) from buffy coats were diluted 1/4 with phosphate-buffered saline (PBS) (calcium/magnesium-free plus 1 mM ethylenediaminetetraacetic acid) and 20 mL of diluted blood layered on top of 14 mL of Ficoll and were centrifuged at 1800 rpm for 30 minutes. The interface was collected and diluted again 1/4 with PBS (calcium/magnesium-free) and spun at 1250 rpm for 5 minutes; next, the pellet washed two more times with PBS. The Ficollpurified PBMCs were resuspended at 10 7 cells/mL in T-cell medium (TCM) (1:1 AIM-V and RPMI 1640 with N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid, sodium pyruvate, glutamine, penicillin-streptomycin, and 10% human sera). The PBMCs were transferred to a T175 flask at 40 mL/flask and incubated for 1-1.5 hours at 37°C to remove monocytes.
The nonadherent cells were resuspended at 3 ϫ 10 6 cells/mL and added to anti-CD3 and anti-CD28 Ab-coated Dynal beads at a density of three cells per bead in TCM. The T cells were stimulated with the anti-CD3/CD28 beads for 48 hours at 37°C. On day 2, the beads were removed magnetically from cells. The PBMCs were then centrifuged and resuspended into TCM with 100 international units (IU)/mL interleukin-2 (IL-2) at 1 ϫ 10 6 cells/mL. After 24 hours, the T cells were spun down and resuspended at 10 6 cells/mL TCM with 100 IU/mL IL-2. The T cells were added to an equal volume of supernatant containing the chimeric receptor-encoding retrovirus and supplemented with IL-2 and polybrene (100-IU/mL and 2-g/mL final concentration, respectively) to bring the cell density to 0.5 ϫ 10 6 cells/mL. After a 24-hour incubation at 37°C, half of the medium was removed and replaced with an equivalent amount of the vector-containing medium. This step was repeated 48 hours later. On day 6, the cells were removed from the transduction mix and resuspended in TCM with IL-2 at 10 6 cells/mL. The culture was then split every 2-3 days to 10 6 cells/mL for an additional 4 -10 days.
Flow cytometry
T cells (5 ϫ 10 5 ) transduced with bispecific chimeric receptor constructs were assessed for surface expression by staining with 100 ng of CC49 anti-idiotype Ab AI49-3 (obtained from Jeff Schlom, National Laboratory for Tumor Biology, National Cancer Institute, National Institutes of Health, Bethesda, Md) in the presence of 3 g of normal mouse IgG at room temperature for 20 minutes. The cells were washed twice with PBS/2% bovine serum albumin and subsequently incubated with 1 g of goat anti-mouse IgG-phycoerythrin in the presence of 3 g of normal goat IgG in 100 L of PBS/2% fetal calf serum at room temperature for 20 minutes. Alternatively, cells were stained with an anti-CEA(a 3 b 3 ) domain-specific biotinylated monoclonal Ab (T84.66) for 1 hour, followed by streptavidin-fluorescein isothiocyanate (FITC) reagent for 30 minutes and subsequent fluorescence-activated cell sorter (FACS) analysis.
T cells transduced with retroviruses encoding the HIVspecific CIRs and BCIRs were assessed for surface expression by incubation with 3 g of biotinylated recombinant gp120 (Intracell, Seattle, Wash) for 1 hour, followed by streptavidin-FITC reagent for 30 minutes, and analyzed on FACStar (Becton Dickinson, San Jose, Calif).
Cytotoxicity assays
Cytotoxic activity was determined by a standard 4-hour chromium release assay as follows: 1 ϫ 10 6 CEA, TAG-72, or 293 cells transfected with HIV env -bearing target cells were incubated with 100 Ci of 51 Cr in 100 L of medium for 1 hour at 37°C. The target cells were then washed extensively with medium and 5 ϫ 10 3 cells were mixed with different numbers of T effector cells in a total volume of 200 mL in a roundbottom, 96-well plate. Cells were pelleted after a 4-h incubation at 37°C, and 100 mL of the resulting supernatant was used for counting in a gamma counter for assessment of 51 Cr release. The percentage of specific lysis was calculated from triplicate samples using the following formula: specific lysis ϭ ([released counts Ϫ spontaneous release counts]/[maximal release counts Ϫ spontaneous release counts]) ϫ 100. Spontaneous release refers to the counts released by targets in the absence of effectors; maximal release from targets was assessed by total lysis of targets by 100 L of 0.5% Triton X-100.
In the target competition assays, the 5 ϫ 10 3 HIV env target cells labeled with 51 Cr were incubated for 1 hour in 100 L of medium that contained 100 g/mL 447D or 98.6 Abs (alone or in combination) in a round-bottom, 96-well plate. After a 1-hour incubation at 37°C, 100 L of medium containing T effector cells was added to the target cells and incubated for another 4 hours at 37°C. The plates were then centrifuged to pellet the cells, and 100 L of the resulting supernatant was used for counting in a gamma counter for assessment of 51 Cr release as indicated above.
RESULTS
BCIR structure and expression
Many of the Ag recognition units comprising the BCIRs were initially tested in CIRs that recognized only one Ag domain: CC49-to bind TAG-72, 18 Col-1-and CEA(a 3 b 3 )-to bind CEA, CD4-and 447D-to bind HIV env gp120, 17, 22 and 98.6-to bind HIV env gp41.
17
The CD4-447D, 447D-98.6, and CC49-CEA(a 3 b 3 ) Ag recognition domains were subsequently fused through a linker to create the BCIR-1, BCIR-2, and BCIR-3 receptors. This is shown graphically in Figure 1 .
To confirm the expression of both the CC49 and CEA(a 3 b 3 ) domains in the BCIR-1 receptor, TSA cells 24 transfected with the BCIR-1-encoding retroviral construct were stained with an anti-CC49 idiotype Ab and an anti-CEA Ab specific for the a 3 b 3 domain of CEA. As shown in Figure 2A , the anti-CC49 idiotype Ab clearly detected surface expression of the BCIR-1 (indicated by arrow). Using the anti-CEA Ab to stain these same cells ( Fig 2B) , we observed a bimodal peak. However, the CEA-positive peak corresponding to the BCIR-1-expressing cells (indicated by arrow) was readily distinguished from the nontransfectant control (black line).
Biotinylated soluble gp120 and streptavidin-FITC were used to assess the transfectants expression of BCIR-2 and BCIR-3 (Fig 2, C-F) . All of the anti-HIV env receptors would be expected to bind soluble gp120. Indeed, the biotinylated soluble gp120/streptavidin-FITC labeled the CD4--, 447D--, and BCIR-2-and BCIR-3-transduced T cells (indicated by arrow), but did not bind the nontransduced T cells (gray shaded plot). (Fig 3, CC49-, filled bars) . 18 To create a CEA-specific CIR, the CC49 scFv of the CC49-CIR was replaced with the anti-CEA scFv Col-1. Although the Col-1 Ab binds CEA, it does not bind related CEA family members BGP, CGM-6, or NCA. When T cells were genetically modified to express the Col-1-CIR, they readily lysed CEA-expressing Chinese hamster ovary cells 25 (Fig 3, Col-1-, open bars) . This lytic activity was CEA-specific, and the Col-1-T cells did not lyse TAG-72-positive Jurkat target cells (Fig 3, Col-1-,  filled bars) . Importantly, they also did not lyse Chinese hamster ovary target cells expressing the CEA family members BGP (Fig 3, Col-1-, gray bars) , NCA (Fig 3, Col-1-, vertical striped bars), or CGM-6 (Fig 3, Col-1-,  horizontal striped bars) .
Ag-specific lysis of tumor cells by BCIR-1-expressing T cells CC49-T cells specifically lyse TAG-72-expressing tumor cell targets
Although the CC49-T cells lysed TAG-72-expressing targets and the Col-1-T cells specifically lysed CEAexpressing LR73 targets, BCIR-1-transduced T cells killed both CEA-expressing targets (Fig 3, BCIR-1 , open bars) and TAG-72-expressing targets (Fig 3, BCIR-1 , filled bars) with an efficiency that was similar to that observed for the monospecific CIR-transduced T cells on their respective targets. Despite the expansion in the target repertoire of BCIR-1 T cells, there was no apparent loss of target specificity. Not only did the BCIR-1 not kill the control (NEO) LR73 cells, but also no significant BCIR-1 T-cell-mediated killing of target cells expressing BGP, CGM-6, or NCA was observed.
BCIR-expressing T cells recognize mutant and wild-type (wt) HIV env
All of the anti-HIV CIR-transduced T cells killed wt HIV env -positive target cells (Fig 4A, CD4 -, 98.6-, and 447D-, filled bars). The BCIR-2 and BCIR-3 genemodified T cells also efficiently killed wt HIV env -expressing TSA target cells (Fig 4A, BCIR-2 and BCIR-3, filled bars) as expected. Nontransduced T cells did not lyse HIV env -expressing target cells (Fig 4A, Mock, filled  bars) , indicating that target cell lysis was mediated by the CIRs and BCIRs. In addition, CIR-and BCIR-mediated lysis was dependent upon target cell expression of HIV env , because control (NEO) TSA cells were not killed (Fig 4E) .
Although all CIR-and BCIR-expressing T cells killed target cells expressing wt HIV env , the relative killing efficacy of the receptors was not equivalent; the CD4--expressing T cells were consistently the most potent in killing wt HIV env -expressing target cells (Fig 4B, filled  circles) . This increased activity, observed in previous studies, is apparently due to the longer receptor half-life and higher gp120 affinity of the CD4-receptor. 22 The high affinity for gp120-CD4 interaction, reproduced by BCIR-2, may be responsible for the high lytic activity of BCIR-2-expressing T cells (Fig 4B, open diamonds) . The BCIR-3 T cells, however, were generally less efficient in killing wt HIV env -expressing targets than either the BCIR-2-or scFv-CIR-expressing T cells (Fig 4B,  open squares) . The lower killing activity of the BCIR-3 T cells was likely due to the lower affinity scFv-gp120 and -gp41 interactions of BCIR-3.
To determine whether Ag engagement by either of the Ag recognition units, CD4 or 447D, in BCIR-2 could elicit cytolysis, target cells that expressed one of two HIV env mutants lacking either the CD4-or 447D-binding domains were created. The CD4-binding site in HIV env was abolished (CD4 Ϫ env) by changing Glu-370 to Arg, 26 and the 447D-binding site was eliminated (447D Ϫ env) by replacing Arg-315 with Glu. 11 Due to the suboptimal cell expression of the mutant HIV env , the total target cell lysis was low in these experiments. Despite the low level of mutant HIV env expression by the target cells, BCIR-2, CD4-, and 447D-killed target cells expressing the appropriate HIV env . Both the 447D-T cells (Fig 4C, filled triangles) and the BCIR-2 T cells, which possess the 447D scFv domain (Fig 4C,  open diamonds) killed target cells expressing the CD4 Ϫ env, whereas lysis by CD4-T cells was reduced by 80% (Fig 4C, filled circles) . Conversely, target cells that expressed the 447D Ϫ HIV env were lysed by both the CD4-T cells (Fig 4D, filled circles) and the BCIR-2 T cells, which possess the CD4 ligand (Fig 4D, open  diamonds) , whereas lysis of these same targets by 447D-T cells was significantly compromised (Fig 4D,  filled triangles) . This experiment demonstrates that both the 447D and CD4 Ag recognition domains of BCIR-2 mediate the binding and killing of cells expressing HIV env Ag loss variants. None of the CIR or BCIR gene-modified T cells lysed the control (NEO) TSA cells (Fig 4E) .
BCIR-3-expressing T cells recognize multiple epitopes of HIV env BCIR-3-expressing T cells were shown to kill targets expressing wt HIV env (Fig 4, A and B) . That experiment did not test whether both the 447D and 98.6 scFv-based Ag recognition units of BCIR-3 would function to mediate wt HIV env target cell lysis. This was assessed directly by measuring the inhibition of BCIR-3 T-cell lysis of wt HIV env -expressing targets in the presence of blocking 447D and 98.6 Abs. As expected in this Ab inhibition assay, the 98.6 Ab (Fig 5, filled bars) blocked the function of the 98.6-T cells (77% inhibition of lysis), whereas the 447D Ab had no effect on 98.6-T-cell activity. Conversely, the 447D Ab (Fig 5, open  bars) significantly blocked wt HIV env target cell lysis by 447D-T cells (41% inhibition of lysis), whereas the 98.6 Ab had no effect on 447D-T-cell activity. No inhibition of CD4-T-cell lysis of wt HIV env target cells was observed with either Ab.
Significantly, neither Ab alone blocked the BCIR-3 T-cell lysis of wt HIV env target cells by Ͼ16%. This finding is in contrast to the 41-77% inhibition of the 447D-and 98.6-T-cell activity observed with the corresponding single Abs. The 447D and 98.6 Abs, when used together, did reduce the BCIR-3 T-cell lysis of wt HIV env target cell targets by 44%, equivalent to the blocking of 447D-T-cell activity with the 447D Ab. Interestingly, a partial block (15% inhibition) of BCIR-2 activity was achieved with the 447D Ab, which presumably blocked the binding of the 447D Ag recognition domain of BCIR-2 T cells. This suggests that although the second Ag recognition domain, CD4, in BCIR-2 would mediate killing, the Ag recognition synergizes to affect T-cell lysis. This is also presumably why each of the Abs is able to partially block the BCIR-3 T-cell lysis of wt HIV env target cells. These results demonstrate that the two scFv-based Ag recognition units present in BCIR-2 and BCIR-3 can recognize distinct protein epitopes on the target Ag and mediate T-cell killing.
DISCUSSION
T-cell immunotherapy of cancer and viral disease has been pursued by numerous groups through the use of either clonal Ag-specific, patient-derived T cells or T cells expressing a CIR with a unique Ag specificity. The available data with these therapeutic approaches indicate that these therapies are well tolerated and, in some instances, capable of eliminating the diseased cells. 27, 28 Despite this success, the potential for Ag loss variants escaping T-cell-mediated lysis is a significant concern and has been reported. 29 To address this potential problem, one could generate multiple cancer-or virusspecific CIRs, as we have done, and then treat patients with T cells genetically modified to express different CIRs. In each case, this is technically difficult to do and strains the practicality of this therapy. As an alternative approach, we have developed three different BCIRs comprising either two distinct scFv Ag recognition domains or an scFv and a ligand-based Ag recognition domain to redirect T cells to recognize multiple tumor or viral Ags and potentially prevent Ag loss variants from escaping destruction. Indeed, the results presented herein demonstrate that antitumoral and antiviral BCIRs can be created to broaden the target recognition capability of T cells expressing these receptors without loss of Ag specificity.
We observed during this study that not all of the BCIRs that were generated were able to produce a receptor capable of mediating target cell lysis. T cells transduced with the retrovirus encoding a CC49-Col-1-BCIR did not express CC49-Col-1-protein detectable by either Western blotting or FACS analysis, and, as would be predicted from this result, these cells did not mediate the lysis of TAG-72-or CEA-expressing cells. At the same time, T cells genetically modified with either of the constitutive receptors, CC49-or Col-1-, expressed high levels of the CIRs and efficiently killed the appropriate target cells. In some instances, however, creation of a BCIR improved the expression and function of a CIR. T cells transduced with the CEA-CIR did not express appreciable levels of the receptor and did not kill CEA-expressing target cells, whereas the CC49-CEA(a 3 b 3 )-receptor (BCIR-1)-expressing T cells mediated CEA and TAG-72 Ag-specific lysis of target cells. These results and our previous experience optimizing the function of ligand-and scFv-based HIVspecific CIRs 22 have shown that the creation of these receptors remains an empirical process.
Because it has been demonstrated that T-cell therapies can be efficacious against both viral and viralassociated disease, efforts must be applied to broaden the applicability of this approach to malignant pathologies. For genetically modified T cells, those efforts must focus on the development of improved viral vectors to increase T-cell transduction efficiencies and the development of CIRs with increased potency. It is our hope that the use of BCIRs will increase the potential for clinical success of CIR-based T-cell therapy.
